Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX was delisted on the 22nd of January, 2024.
253 hedge funds and large institutions have $4.7B invested in Mirati Therapeutics, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 60 funds opening new positions, 97 increasing their positions, 71 reducing their positions, and 66 closing their positions.
80% more call options, than puts
Call options by funds: $56.9M | Put options by funds: $31.6M
37% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 71
9% less first-time investments, than exits
New positions opened: 60 | Existing positions closed: 66
3% less funds holding
Funds holding: 260 → 253 (-7)
36% less funds holding in top 10
Funds holding in top 10: 14 → 9 (-5)
44% less capital invested
Capital invested by funds: $8.33B → $4.7B (-$3.63B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$63.9M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$60M |
| 3 |
AC
Armistice Capital
New York
|
+$54M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
+$51.2M |
| 5 |
State Street
Boston,
Massachusetts
|
+$39.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$92.4M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$70.4M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$67.9M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$54.3M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$46.3M |
MRTX Hedge Fund Activity: Q1 2022 in Review
253 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q1 2022, worth a combined $4.7B — down 44% from $8.33B a quarter earlier.
Sellers outnumbered buyers: 66 funds closed out of MRTX and 60 opened new positions — a net loss of 6 holders — while 71 trimmed existing stakes and 97 added.
The largest buyer was Camber Capital Management, adding an estimated $63.9M. The largest seller was Perceptive Advisors, cutting an estimated $92.4M.
- 253 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q1 2022, down from 260 in Q4 2021.
- Funds reported $4.7B of Mirati Therapeutics, Inc. Common Stock stock for Q1 2022, down 44% quarter-over-quarter.
- 60 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q1 2022 and 66 closed out, a net change of -6 holders.
- The largest Mirati Therapeutics, Inc. Common Stock buyer in Q1 2022 was Camber Capital Management, an estimated $63.9M added.
- The largest Mirati Therapeutics, Inc. Common Stock seller in Q1 2022 was Perceptive Advisors, an estimated $92.4M sold.
Based on aggregated 13F filings for Q1 2022.